{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:03:01Z","timestamp":1781877781050,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00105-022-05020-6","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T09:03:38Z","timestamp":1657703018000},"page":"614-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Update zur Therapie der chronischen Prurigo","Update on the treatment of chronic prurigo"],"prefix":"10.1007","volume":"73","author":[{"given":"Claudia","family":"Zeidler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Pedro","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"issue":"11","key":"5020_CR1","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1111\/jdv.17485","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin\u00a0M, Garbe\u00a0C, Hagenstr\u00f6m\u00a0K, Petersen\u00a0J, Pereira\u00a0MP, St\u00e4nder\u00a0S (2021) Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: A population-based claims data analysis. J\u00a0Eur Acad Dermatol Venereol 35(11):2270\u20132276. https:\/\/doi.org\/10.1111\/jdv.17485","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5020_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21032","author":"CL Morgan","year":"2022","unstructured":"Morgan\u00a0CL, Thomas\u00a0M, St\u00e4nder\u00a0S, Jabbar-Lopez\u00a0ZK, Piketty\u00a0C, Gabriel\u00a0S, Currie\u00a0C, Puelles\u00a0J (2022) Epidemiology of prurigo nodularis in England: a\u00a0retrospective database analysis. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.21032","journal-title":"Br J Dermatol"},{"key":"5020_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jdin.2020.10.009","volume":"2","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder\u00a0S, Augustin\u00a0M, Berger\u00a0T, Elmariah\u00a0S, Korman\u00a0NJ, Weisshaar\u00a0E, Yosipovitch\u00a0G (2021) Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis. JAAD Int 2:28\u201330. https:\/\/doi.org\/10.1016\/j.jdin.2020.10.009","journal-title":"JAAD Int"},{"issue":"3","key":"5020_CR4","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/jdv.16929","volume":"35","author":"C Zeidler","year":"2021","unstructured":"Zeidler\u00a0C, Pereira\u00a0MP, Dugas\u00a0M, Augustin\u00a0M, Storck\u00a0M, Weyer-Elberich\u00a0V, Schneider\u00a0G, St\u00e4nder\u00a0S (2021) The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non-lesional skin: a comparative, retrospective, explorative statistical analysis of 4,484\u00a0patients in a\u00a0real-world cohort. J\u00a0Eur Acad Dermatol Venereol 35(3):738\u2013743. https:\/\/doi.org\/10.1111\/jdv.16929","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"5020_CR5","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1097\/itx.0000000000000042","volume":"5","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder\u00a0S, Pereira\u00a0MP, Berger\u00a0T et\u00a0al (2020) IFSI-guideline on chronic prurigo including prurigo nodularis. Itch 5(4):e42. https:\/\/doi.org\/10.1097\/itx.0000000000000042","journal-title":"Itch"},{"issue":"8","key":"5020_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/ddg.13304_g","volume":"15","author":"S St\u00e4nder","year":"2017","unstructured":"St\u00e4nder\u00a0S, Zeidler\u00a0C, Augustin\u00a0M, Bayer\u00a0G, Kremer\u00a0AE, Legat\u00a0FJ, Maisel\u00a0P, Mettang\u00a0T, Metz\u00a0M, Nast\u00a0A, Niemeier\u00a0V, Raap\u00a0U, Schneider\u00a0G, St\u00e4nder\u00a0HF, Staubach\u00a0P, Streit\u00a0M, Weisshaar\u00a0E (2017) S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus \u2013 Update \u2013 Kurzversion. J\u00a0Dtsch Dermatol Ges 15(8):860\u2013873. https:\/\/doi.org\/10.1111\/ddg.13304_g","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"5020_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/ijd.14708","volume":"59","author":"KMV Eusebio-Alpapara","year":"2020","unstructured":"Eusebio-Alpapara\u00a0KMV, Castillo\u00a0RL, Dofitas\u00a0BL (2020) Gabapentin for uremic pruritus: a\u00a0systematic review of randomized controlled trials. Int J Dermatol 59(4):412\u2013422. https:\/\/doi.org\/10.1111\/ijd.14708","journal-title":"Int J Dermatol"},{"issue":"12","key":"5020_CR8","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/exd.14034","volume":"28","author":"M Campion","year":"2019","unstructured":"Campion\u00a0M, Smith\u00a0L, Gatault\u00a0S, M\u00e9tais\u00a0C, Buddenkotte\u00a0J, Steinhoff\u00a0M (2019) Interleukin\u20114 and interleukin-13 evoke scratching behaviour in mice. Exp Dermatol 28(12):1501\u20131504. https:\/\/doi.org\/10.1111\/exd.14034","journal-title":"Exp Dermatol"},{"issue":"1","key":"5020_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen\u00a0LK, Mack\u00a0MR, Feng\u00a0J, Whelan\u00a0TM, Niu\u00a0H, Guo\u00a0CJ, Chen\u00a0S, Trier\u00a0AM, Xu\u00a0AZ, Tripathi\u00a0SV, Luo\u00a0J, Gao\u00a0X, Yang\u00a0L, Hamilton\u00a0SL, Wang\u00a0PL, Brestoff\u00a0JR, Council\u00a0ML, Brasington\u00a0R, Schaffer\u00a0A, Brombacher\u00a0F, Hsieh\u00a0C\u2011S, Gereau\u00a0RW, Miller\u00a0MJ, Chen\u00a0Z\u2011F, Hu\u00a0H, Davidson\u00a0S, Liu\u00a0Q, Kim\u00a0BS (2017) Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell 171(1):217\u2013228.e13. https:\/\/doi.org\/10.1016\/j.cell.2017.08.006","journal-title":"Cell"},{"key":"5020_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1853024","author":"H Husein-ElAhmed","year":"2020","unstructured":"Husein-ElAhmed\u00a0H, Steinhoff\u00a0M (2020) Dupilumab in prurigo nodularis: a\u00a0systematic review of current evidence and analysis of predictive factors to response. J\u00a0Dermatolog Treat. https:\/\/doi.org\/10.1080\/09546634.2020.1853024","journal-title":"J Dermatolog Treat"},{"key":"5020_CR11","unstructured":"Sanofi (2022) Second positive Phase 3 Dupixent\u00ae (dupilumab) trial confirms significant improvements for patients with prurigo nodularis. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-01-19-07-00-00-2368986. Zugegriffen: 20. M\u00e4rz 2022"},{"issue":"4","key":"5020_CR12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2340\/00015555-3120","volume":"99","author":"A Tsianakas","year":"2019","unstructured":"Tsianakas\u00a0A, Zeidler\u00a0C, Riepe\u00a0C, Borowski\u00a0M, Forner\u00a0C, Gerss\u00a0J, Metz\u00a0M, Staubach\u00a0P, Raap\u00a0U, Kaatz\u00a0M, Urban\u00a0M, Luger\u00a0TA, St\u00e4nder\u00a0S (2019) Aprepitant in anti-histamine-refractory chronic nodular prurigo: a multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II trial (APREPRU). Acta Derm Venereol 99(4):379\u2013385. https:\/\/doi.org\/10.2340\/00015555-3120","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"5020_CR13","doi-asserted-by":"publisher","first-page":"e10968","DOI":"10.1371\/journal.pone.0010968","volume":"5","author":"S St\u00e4nder","year":"2010","unstructured":"St\u00e4nder\u00a0S, Siepmann\u00a0D, Herrgott\u00a0I, Sunderk\u00f6tter\u00a0C, Luger\u00a0TA (2010) Targeting the neurokinin receptor 1 with aprepitant: a\u00a0novel antipruritic strategy. Plos One 5(6):e10968. https:\/\/doi.org\/10.1371\/journal.pone.0010968","journal-title":"Plos One"},{"issue":"4","key":"5020_CR14","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jaad.2009.08.052","volume":"63","author":"NQ Phan","year":"2010","unstructured":"Phan\u00a0NQ, Bernhard\u00a0JD, Luger\u00a0TA, St\u00e4nder\u00a0S (2010) Antipruritic treatment with systemic \u03bc\u2011opioid receptor antagonists: a\u00a0review. J\u00a0Am Acad Dermatol 63(4):680\u2013688. https:\/\/doi.org\/10.1016\/j.jaad.2009.08.052","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"5020_CR15","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1001\/jamadermatol.2021.3829","volume":"157","author":"MP Pereira","year":"2021","unstructured":"Pereira\u00a0MP, Zeidler\u00a0C, St\u00e4nder\u00a0S (2021) Improvement of chronic kidney disease-associated pruritus after treatment with intravenous naloxone. JAMA Dermatol 157(11):1380\u20131381. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3829","journal-title":"JAMA Dermatol"},{"issue":"4","key":"5020_CR16","first-page":"533","volume":"41","author":"D Metze","year":"1999","unstructured":"Metze\u00a0D, Reimann\u00a0S, Beissert\u00a0S, Luger\u00a0T (1999) Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J\u00a0Am Acad Dermatol 41(4):533\u2013539","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"5020_CR17","doi-asserted-by":"publisher","first-page":"adv00269","DOI":"10.2340\/00015555-3571","volume":"100","author":"S Gr\u00fcndel","year":"2020","unstructured":"Gr\u00fcndel\u00a0S, Pereira\u00a0MP, Storck\u00a0M, Osada\u00a0N, Schneider\u00a0G, St\u00e4nder\u00a0S, Zeidler\u00a0C (2020) Analysis of 325 patients with chronic nodular prurigo: clinics, burden of disease and course of treatment. Acta Derm Venereol 100(16):adv269. https:\/\/doi.org\/10.2340\/00015555-3571","journal-title":"Acta Derm Venereol"},{"key":"5020_CR18","doi-asserted-by":"publisher","first-page":"639097","DOI":"10.3389\/fmed.2021.639097","volume":"8","author":"JM Nemmer","year":"2021","unstructured":"Nemmer\u00a0JM, Kuchner\u00a0M, Datsi\u00a0A, Ol\u00e1h\u00a0P, Julia\u00a0V, Raap\u00a0U, Homey\u00a0B (2021) Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. Front Med 8:639097. https:\/\/doi.org\/10.3389\/fmed.2021.639097","journal-title":"Front Med"},{"key":"5020_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.004","author":"LC Tsoi","year":"2021","unstructured":"Tsoi\u00a0LC, Hacini-Rachinel\u00a0F, Fogel\u00a0P, Rousseau\u00a0F, Xing\u00a0X, Patrick\u00a0MT, Billi\u00a0AC, Berthier\u00a0CC, Kahlenberg\u00a0JM, Lazzari\u00a0A, Wiegmann\u00a0H, St\u00e4nder\u00a0S, Piketty\u00a0C, Julia\u00a0V, Krishnaswamy\u00a0JK, Gudjonsson\u00a0JE (2021) Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J\u00a0Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2021.10.004","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"5020_CR20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","volume":"382","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder\u00a0S, Yosipovitch\u00a0G, Legat\u00a0FJ, Lacour\u00a0J\u2011P, Paul\u00a0C, Narbutt\u00a0J, Bieber\u00a0T, Misery\u00a0L, Wollenberg\u00a0A, Reich\u00a0A, Ahmad\u00a0F, Piketty\u00a0C (2020) Trial of nemolizumab in moderate-to-severe prurigo nodularis. N\u00a0Engl J Med 382(8):706\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa1908316","journal-title":"N Engl J Med"},{"issue":"6","key":"5020_CR21","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/exd.14279","volume":"30","author":"T Hashimoto","year":"2021","unstructured":"Hashimoto\u00a0T, Nattkemper\u00a0LA, Kim\u00a0HS, Kursewicz\u00a0CD, Fowler\u00a0E, Shah\u00a0SM, Nanda\u00a0S, Fayne\u00a0RA, Paolini\u00a0JF, Romanelli\u00a0P, Yosipovitch\u00a0G (2021) Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol 30(6):804\u2013810. https:\/\/doi.org\/10.1111\/exd.14279","journal-title":"Exp Dermatol"},{"key":"5020_CR22","volume-title":"Kiniksa announces phase 2 clinical data from vixarelimab in prurigo nodularis","author":"BioSpace","year":"2020","unstructured":"BioSpace (2020) Kiniksa announces phase 2 clinical data from vixarelimab in prurigo nodularis. Presented at European Academy of Dermatology and Venereology Virtual Congress."},{"issue":"3","key":"5020_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/jdv.17816","volume":"36","author":"E Weisshaar","year":"2022","unstructured":"Weisshaar\u00a0E, Szepietowski\u00a0JC, Bernhard\u00a0JD, Hait\u00a0H, Legat\u00a0FJ, Nattkemper\u00a0L, Reich\u00a0A, Sadoghi\u00a0B, Sciascia\u00a0TR, Zeidler\u00a0C, Yosipovitch\u00a0G, St\u00e4nder\u00a0S (2022) Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a\u00a0phase 2 randomized controlled trial with an open-label extension phase. J\u00a0Eur Acad Dermatol Venereol 36(3):453\u2013461. https:\/\/doi.org\/10.1111\/jdv.17816","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"5020_CR24","doi-asserted-by":"publisher","first-page":"e2021145","DOI":"10.5826\/dpc.1104a145","volume":"11","author":"M Nogueira","year":"2021","unstructured":"Nogueira\u00a0M, Torres\u00a0T (2021) Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib. Dermatol Pract Concept 11(4):e2021145. https:\/\/doi.org\/10.5826\/dpc.1104a145","journal-title":"Dermatol Pract Concept"},{"key":"5020_CR25","doi-asserted-by":"publisher","first-page":"754116","DOI":"10.3389\/fmed.2022.754116","volume":"9","author":"F G\u00f3mez-Garc\u00eda","year":"2022","unstructured":"G\u00f3mez-Garc\u00eda\u00a0F, G\u00f3mez-Arias\u00a0PJ, Montilla-L\u00f3pez\u00a0A, Hern\u00e1ndez-Parada\u00a0J, Sanz-Cabanillas\u00a0JL, Ruano\u00a0J, Parra-Peralbo\u00a0E (2022) A scoping review on use of drugs targeting the JAK\/STAT pathway in psoriasis. Front Med 9:754116. https:\/\/doi.org\/10.3389\/fmed.2022.754116","journal-title":"Front Med"},{"issue":"7","key":"5020_CR26","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/ced.14320","volume":"45","author":"OE Molloy","year":"2020","unstructured":"Molloy\u00a0OE, Kearney\u00a0N, Byrne\u00a0N, Kirby\u00a0B (2020) Successful treatment of recalcitrant nodular prurigo with tofacitinib. Clin Exp Dermatol 45(7):918\u2013920. https:\/\/doi.org\/10.1111\/ced.14320","journal-title":"Clin Exp Dermatol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-05020-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-022-05020-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-05020-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T22:17:48Z","timestamp":1658960268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-022-05020-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["5020"],"URL":"https:\/\/doi.org\/10.1007\/s00105-022-05020-6","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"assertion":[{"value":"31 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Zeidler: Pr\u00fcfarzt: Galderma, GSK, Kiniksa, Menlo, Novartis, Sanofi, Trevi; Referenten\u2011\/Reisehonorare: AbbVie, Beiersdorf, Dermasence, Novartis, Leo Pharma. M.P.\u00a0Pereira: Pr\u00fcfarzt: Sanofi, Trevi Therapeutics; Berater: Galderma; Referenten\u2011\/Reisehonorare: AbbVie, Beiersdorf, Eli Lilly, Galderma, Menlo Therapeutics, Novartis, P.G.\u00a0Unna Academy und Trevi Therapeutics. S.\u00a0St\u00e4nder: Forschungsstipendien: Almirall, Beiersdorf, Deutsche Forschungsgemeinschaft (DFG), Europ\u00e4ische Akademie f\u00fcr Dermatologie und Venerologie (EADV), Bundesministerium f\u00fcr Bildung und Forschung (BMBF), Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung M\u00fcnster (IZKF), Leo Pharma, Menlo, Novartis, Sanofi, Trevi; Pr\u00fcfarzt: Celldex, Clexio, Dermasence, Galderma, GSK, Kiniksa, Menlo, Novartis, Sanofi, Trevi; Beratung: AbbVie, Almirall, Beiersdorf, Bellus Health, Benevolent, Bionorica, Cara, Celgene, Cello Health, Clexio, DS Biopharma, Eli Lilly, Escient, Galderma, Gr\u00fcnenthal, Kiniksa, Klinge Pharma, Menlo, Sanofi, Sienna, Trevi, P.G.\u00a0Unna Academy, Perrigo, Pfizer, Vanda, Vifor, WebMD; Referentenhonorare: Almirall, Eli Lilly, Sanofi, Galderma, Menlo, Omnicuris, Beiersdorf, Leo Pharma, Novartis, P.G.\u00a0Unna Academy, Pfizer, Pierre Fabre.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}